Trending: Vodafone Group Revenue Fell After Sale of Hungarian Business
1034 GMT - Vodafone Group is among the most mentioned companies across news items over the past three hours, according to Factiva data, after the company reported a fall in revenue for the third-quarter due to the completed sale of Vodafone Hungary. The U.K.-based telecommunications group has made some progress, but prospects remain uncertain, Interactive Investor Head of Markets Richard Hunter wrote in a research note. Performance at the German segment is likely to deteriorate materially from the next quarter when TV revenue from housing associations start to fade out, Citi analysts Georgios Ierodiaconou and Mollie Witcombe said. A slowdown here will cause concern for investors, as the segment represents the largest contributor to the group, AJ Bell Investment Director Russ Mould added. Shares are down 1.15% at 67.81 pence. Over the past twelve months, shares have fallen 25.6%. Dow Jones & Co. owns Factiva. (najat.kantouar@wsj.com)
(END) Dow Jones Newswires
February 05, 2024 05:50 ET (10:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure
-
Exxon Earnings: Ignore Earnings Shortfall as Long-Term Growth and Improvement on Track
-
American Airlines Earnings: We See Costs Overshadowing Market Share This Year